Institutional Clinical and Translational Sciences Award

机构临床和转化科学奖

• 批准号: 10487653
• 负责人: GARRET A FITZGERALD
• 金额: $ 6.13万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-02-01 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10487653
• 关键词: Adult; Award; Biological Models; Cell model; Childhood; Clinical Sciences; Clinical and Translational Science Awards; Disease; Fostering; Funding; Growth; Home; Human; Institutes; Parents; Persons; Phenotype; Physiology; Research; Research Personnel; Translational Research; drug action; translational medicine; translational therapeutics

ABSTRACT OF THE FUNDED PARENT AWARD The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people. The two priorities of our CTSA are to foster the field of translational therapeutics and to bridge the pediatric to adult divide across the entire spectrum of clinical and translational science. This section describes how these priorities have influenced the growth of this CTSA Hub and outlines our plans for the coming funding period.

受资助父母奖摘要 转化医学和治疗研究所是CTSA在宾夕法尼亚的学术总部。对于 在过去十年中，ITMAT的具体目标一直是而且仍然是：(一)增加有能力的调查员人数 在细胞和模型系统中的概念证明和(Ii)阐明 人类生理、疾病或药物作用的机制通过在少数人中强化表型 人民。我们的CTSA的两个优先事项是促进翻译治疗领域的发展和弥合 从儿科到成人，横跨临床和转化科学的整个领域。本部分介绍 这些优先事项如何影响了CTSA中心的发展，并概述了我们对即将到来的资金的计划 句号。